Literature DB >> 15087399

Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach.

Monica Lupi1, Giada Matera, Davide Branduardi, Maurizio D'Incalci, Paolo Ubezio.   

Abstract

Topotecan (TPT) is a topoisomerase I inhibitor, and like the other drugs of this family, it is believed to act in a specific way on cells in S phase at the time of treatment. Exploiting a new method, coupling a particular experimental plan with computer simulation, a complete quantitative study of the time dependence and dose dependence of the activity of cell cycle controls has become feasible, and the overall scenario of events after treatment can be reconstructed in detail. We were able to demonstrate that the response of an ovarian cancer cell line to 1 h of treatment with TPT is not limited to inhibition of DNA synthesis, leading to cell death, but involves G(1) and G(2)-M checkpoints. G(1) and G(2)-M block, recycling, and death follow specific dose-dependent kinetics, lasting no less than 3 days after treatment. We also found that cells treated outside S phase contribute significantly to the overall activity. The utility of this analysis was demonstrated by reproducing more complex treatment schemes in which low TPT concentrations were applied for 1 h three times at 24-h intervals. In this case, the simulation clarified the origin of the auto-potentiation observed with repeated 0.2 micro M treatments, in which the cytotoxicity, particularly against S-phase cells, was higher than the cytotoxicity in cells treated with 10 micro M only once. We believe that this approach will help us to understand the complexity and heterogeneity of the response of a cell population to a drug challenge and could help us to establish the rationale for drug scheduling or drug combinations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087399     DOI: 10.1158/0008-5472.can-03-3810

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

Authors:  M Tavecchio; C Natoli; P Ubezio; E Erba; M D'Incalci
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

2.  Beyond The T/C Ratio: Old And New Anticancer Activity Scores In Vivo.

Authors:  Paolo Ubezio
Journal:  Cancer Manag Res       Date:  2019-09-19       Impact factor: 3.989

3.  Flow-based cytometric analysis of cell cycle via simulated cell populations.

Authors:  M Rowan Brown; Huw D Summers; Paul Rees; Paul J Smith; Sally C Chappell; Rachel J Errington
Journal:  PLoS Comput Biol       Date:  2010-04-15       Impact factor: 4.475

4.  Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy.

Authors:  Sarah Crawford
Journal:  Front Pharmacol       Date:  2013-06-25       Impact factor: 5.810

5.  relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.

Authors:  Peter Hinow; Shizhen Emily Wang; Carlos L Arteaga; Glenn F Webb
Journal:  Theor Biol Med Model       Date:  2007-04-03       Impact factor: 2.432

6.  MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells.

Authors:  James Neil Fisher; Mineko Terao; Maddalena Fratelli; Mami Kurosaki; Gabriela Paroni; Adriana Zanetti; Maurizio Gianni; Marco Bolis; Monica Lupi; Anna Tsykin; Gregory J Goodall; Enrico Garattini
Journal:  Oncotarget       Date:  2015-05-30

7.  Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.

Authors:  Paolo Ubezio; Francesca Falcetta; Laura Carrassa; Monica Lupi
Journal:  Oncotarget       Date:  2016-03-29

8.  Cell killing and resistance in pre-operative breast cancer chemotherapy.

Authors:  Paolo Ubezio; David Cameron
Journal:  BMC Cancer       Date:  2008-07-21       Impact factor: 4.430

9.  Dynamic rendering of the heterogeneous cell response to anticancer treatments.

Authors:  Francesca Falcetta; Monica Lupi; Valentina Colombo; Paolo Ubezio
Journal:  PLoS Comput Biol       Date:  2013-10-17       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.